Custom cancer vaccine plus standard therapy for advanced colorectal cancer

This trial is testing a personalized tumor neoantigen-loaded DC vaccine combined with standard third-line chemotherapy for people with colorectal cancer that has stopped responding to two previous treatments. Researchers will create a custom vaccine designed specifically for your tumor by identifying unique mutations in your cancer cells and training your immune system to recognize and attack them. You would receive this personalized vaccine along with conventional chemotherapy to see if this combination can help control your cancer.

Colorectal cancer that progresses after two rounds of standard treatment is very difficult to manage, and patients need new options. This trial is testing whether a personalized vaccine that trains your own immune system to fight your specific cancer cells—combined with standard therapy—can be more effective than chemotherapy alone.